Differentiating carcinoid syndrome from other diseases: Difference between revisions
No edit summary |
No edit summary |
||
Line 20: | Line 20: | ||
! | ! | ||
| colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="8" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
| | |||
| | | | ||
! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="9" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
Line 30: | Line 31: | ||
| | | | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
! | |||
! | ! | ||
|- | |- | ||
! | |||
! | ! | ||
! | ! | ||
Line 51: | Line 54: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypotension | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypotension | ||
!Tachycardia | !Tachycardia | ||
!Systolic murmur of tricuspid regurgitation | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary 5-hydroxyindoleacetic acid (5-HIAA) | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary 5-hydroxyindoleacetic acid (5-HIAA) | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum Chromogranin A (CgA) | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum Chromogranin A (CgA) | ||
Line 72: | Line 76: | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
Line 94: | Line 99: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
Line 117: | Line 123: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
Line 131: | Line 138: | ||
|- | |- | ||
|Malignant neoplasms of small intestine | |Malignant neoplasms of small intestine | ||
| | |||
| | | | ||
| | | | ||
Line 154: | Line 162: | ||
|- | |- | ||
|Benign cutaneous flushing | |Benign cutaneous flushing | ||
| | |||
| | | | ||
| | | | ||
Line 177: | Line 186: | ||
|- | |- | ||
|Recurrent idiopathic anaphylaxis | |Recurrent idiopathic anaphylaxis | ||
| | |||
| | | | ||
| | | | ||
Line 210: | Line 220: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" |- | | | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 233: | Line 244: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" |- | | | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 255: | Line 267: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 269: | Line 282: | ||
|- | |- | ||
|Anaphylaxis | |Anaphylaxis | ||
| | |||
| | | | ||
| | | | ||
Line 292: | Line 306: | ||
|- | |- | ||
|Angioedema | |Angioedema | ||
| | |||
| | | | ||
| | | | ||
Line 314: | Line 329: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
Line 337: | Line 353: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
Line 360: | Line 377: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | |
Revision as of 15:55, 8 February 2019
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating carcinoid syndrome from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating carcinoid syndrome from other diseases |
FDA on Differentiating carcinoid syndrome from other diseases |
CDC on Differentiating carcinoid syndrome from other diseases |
Differentiating carcinoid syndrome from other diseases in the news |
Blogs on Differentiating carcinoid syndrome from other diseases |
Risk calculators and risk factors for Differentiating carcinoid syndrome from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome must be differentiated from systemic mastocytosis, medullary thyroid carcinoma, irritable bowel syndrome, malignant neoplasms of the small intestine, benign cutaneous flushing, and recurrent idiopathic anaphylaxis.
Differentiating Carcinoid Syndrome from other Diseases
Carcinoid syndrome must be differentiated from:[1]
- Systemic mastocytosis
- Medullary thyroid carcinoma
- Irritable bowel syndrome
- Malignant neoplasms of the small intestine
- Benign cutaneous flushing
- Recurrent idiopathic anaphylaxis
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||||||
Abdominal pain | Diarrhea | Flushing | Dyspnea | Palpitations | Wheezing | Telangiectasia | Hypotension | Tachycardia | Systolic murmur of tricuspid regurgitation | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | Serum Chromogranin A (CgA) | Lab 3 | Abdominal computed tomography (CT) | MRI | somatostatin receptor scintigraphy [SRS], or Octreoscan | Metaiodobenzylguanidine (MIBG) scintigraphy |
| |||||
Carcinoid Syndrome | + | + | + | + | + | + | + | + | + | + | + | |||||||||||
Irritable Bowel Syndrome | - | - | ||||||||||||||||||||
Systemic mastocytosis | - | |||||||||||||||||||||
Malignant neoplasms of small intestine | ||||||||||||||||||||||
Benign cutaneous flushing | ||||||||||||||||||||||
Recurrent idiopathic anaphylaxis | ||||||||||||||||||||||
Crohn disease | - | - | ||||||||||||||||||||
Asthma exacerbation | - | - | ||||||||||||||||||||
Acute Urticaria | ||||||||||||||||||||||
Anaphylaxis | ||||||||||||||||||||||
Angioedema | ||||||||||||||||||||||
References
- ↑ Metcalfe DD (2000). "Differential diagnosis of the patient with unexplained flushing/anaphylaxis". Allergy Asthma Proc. 21 (1): 21–4. PMID 10748948.